Serán Bioscience Announces Investment by Vivo Capital

Serán Bioscience Announces Investment by Vivo Capital
A majority investment by Vivo Capital, a healthcare investment firm headquartered in Silicon Valley, will fund the expansion of Serán's service offering, the doubling of clean room capacity by year-end, and the development and construction a new commercial scale cGMP manufacturing facility by the end of 2022.
News provided by
Share this article
Share this article
BEND, Ore., Jan. 6, 2021 /PRNewswire/ -- Serán Bioscience today announced that healthcare investment firm Vivo Capital has made a majority investment in Serán alongside Serán's founders who will continue to lead the Company.
Founded in 2016, Serán is a leading contract development and manufacturing organization providing a comprehensive suite of development, analytical and clinical manufacturing services to pharmaceutical and biotechnology companies. Serán's deep experience and expertise in materials science, formulation development, engineering, and pharmaceutical manufacturing enables optimum solutions for their customers most difficult drug development challenges. Serán currently has over 50 employees—of which more than half are scientists—at its facilities in Bend, Oregon.

Related Keywords

California ,United States ,Oregon ,Palo Alto ,Williamson Wyatt ,Latham Watkins ,Dan Smithey ,John Melvin ,Suzanne Brady ,Prnewswire Sera ,Mahendra Shah ,William Blair ,B Vivo Capital Fund ,M Vivo Opportunity Fund ,Business Development ,Vivo Capital ,Managing Director ,Vivo Capital Fund ,Vivo Opportunity Fund ,Vivo Innovation ,கலிஃபோர்னியா ,ஒன்றுபட்டது மாநிலங்களில் ,ஓரிகந் ,பாலோ ஆல்டோ ,வில்லியம்சன் வையட் ,லாதம் வாட்கின்ஸ் ,டான் ஸ்மீத்ெய் ,ஜான் மெல்வின் ,ஸுஸ்யாந் பிராடி ,மகேந்திரா ஷா ,வில்லியம் பிளேயர் ,மீ விவோ வாய்ப்பு நிதி ,வணிக வளர்ச்சி ,விவோ மூலதனம் ,நிர்வகித்தல் இயக்குனர் ,விவோ மூலதனம் நிதி ,விவோ வாய்ப்பு நிதி ,விவோ கண்டுபிடிப்பு ,